MAKScientific Is Developing Drugs To Treat Disease By Targeting the Endocannabinoid System
Our approach involves the selective targeting of known components within this biochemical system, including the cannabinoid receptors (CB1 and CB2), key regulatory enzymes (FAAH, MAGL, and NAAA), and the cannabinoid transporter system. MAKScientific has a robust and expanding portfolio of small-molecule modulators for each target, several of which have demonstrated proof-of-concept in selected animal models of human disease. Our advanced drug candidate, AM6527, is a selective CB1 receptor neutral antagonist that offers a promising new therapeutic strategy for the management of substance use disorders, metabolic conditions, and other CB1-related pathologies.
MAKScientific is developing a pipeline of small molecule modulators that target key intervention points in the endocannabinoid system. A lead pre-clinical drug candidate (AM6527) is a selective CB1 receptor neutral antagonist in advanced pre-clinical testing for treating Alcohol Use Disorder.
MAKScientific is a Boston-based pharmaceutical company focusing on the development of new compounds to treat a variety of diseases modulated by the endocannabinoid system.
MAKScientific is seeking a partner to continue the development and commercialization of its lead CB1 antagonist (AM6527) as a treatment for Alcohol Use Disorder and other Substance Use Disorders. The drug has already completed IND-enabling studies and has shown no adverse toxicity to date.